Verastem (VSTM) News Today → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free VSTM Stock Alerts $3.96 -0.03 (-0.75%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 30 at 5:15 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTMMay 30 at 3:46 AM | americanbankingnews.comVerastem (NASDAQ:VSTM) Given New $20.00 Price Target at Alliance Global PartnersMay 29 at 1:42 PM | marketbeat.comAlliance Global Partners Trims Verastem (NASDAQ:VSTM) Target Price to $20.00Alliance Global Partners lowered their price target on shares of Verastem from $34.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday.May 29 at 2:14 AM | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pro Medicus Limited (OtherPMCUF), AdaptHealth (AHCO) and Verastem (VSTM)May 28, 2024 | americanbankingnews.comRoyal Bank of Canada Lowers Verastem (NASDAQ:VSTM) Price Target to $16.00May 28, 2024 | americanbankingnews.comVerastem (NASDAQ:VSTM) Rating Reiterated by HC WainwrightMay 26, 2024 | seekingalpha.comVerastem: Narrowed Market And Less Compelling Efficacy Warrant Rating DowngradeMay 26, 2024 | seekingalpha.comVerastem: A Shocking Drop On 'Positive' Data (Maintain Buy)May 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verastem Amidst Promising Clinical Data and Market Expansion PotentialMay 24, 2024 | finance.yahoo.comWomen get dismissed by doctors—and it’s led to devastating consequences for cancerMay 24, 2024 | markets.businessinsider.comBuy Rating on Verastem: Promising RAMP 201 Study Outcomes and Favorable Investment PotentialMay 24, 2024 | msn.comVerastem whipsaws after updates for cancer drug comboMay 24, 2024 | bizjournals.comOvarian cancer drug developer's stock cut in half after it files for FDA approvalMay 24, 2024 | finance.yahoo.comSector Update: Health Care Stocks Advance Pre-Bell FridayMay 24, 2024 | finance.yahoo.comWhat's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?May 24, 2024 | investorplace.comWhy Is Verastem (VSTM) Stock Down 62% Today?May 24, 2024 | businesswire.comHarvest ETFs announces May 2024 DistributionsMay 24, 2024 | businesswire.comVerastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian CancerMay 24, 2024 | americanbankingnews.comVerastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from AnalystsMay 24, 2024 | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Given Consensus Recommendation of "Buy" by BrokeragesShares of Verastem, Inc. (NASDAQ:VSTM - Get Free Report) have received a consensus recommendation of "Buy" from the six brokerages that are covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokeragesMay 23, 2024 | businesswire.comVerastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and ...May 23, 2024 | msn.comVerastem shares surge more than 50% after pancreatic-cancer treatment study dataMay 23, 2024 | msn.comVerastem stock rallies on positive data for pancreatic cancer drug comboMay 23, 2024 | businesswire.comVerastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic CancerMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verastem Amid Positive Developments and Strong Financial PositionMay 13, 2024 | markets.businessinsider.comBuy Rating on Verastem: Promising Pipeline and Regulatory Milestones Drive Positive OutlookMay 13, 2024 | marketbeat.comVerastem's (VSTM) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $17.50 target price on shares of Verastem in a research report on Monday.May 10, 2024 | markets.businessinsider.comVerastem Inc. Poised for Growth: Buy Rating Affirmed on Clinical and Regulatory MilestonesMay 10, 2024 | investorplace.comVSTM Stock Earnings: Verastem Beats EPS for Q1 2024May 9, 2024 | washingtonpost.comArrowhead Research: Fiscal Q2 Earnings SnapshotMay 9, 2024 | businesswire.comVerastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business UpdatesMay 7, 2024 | businesswire.comVerastem Oncology to Present at the RBC Capital Markets Global Healthcare ConferenceApril 20, 2024 | investing.comVerastem Oncology appoints new CMO to lead cancer drug trialsApril 19, 2024 | finance.yahoo.comVerastem, Inc. (VSTM)April 18, 2024 | marketwatch.comVerastem Oncology Names John Hayslip as Chief Medical OfficerApril 18, 2024 | businesswire.comVerastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical OfficerApril 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)April 12, 2024 | marketbeat.comVerastem (NASDAQ:VSTM) Share Price Passes Above 200-Day Moving Average of $9.47Verastem (NASDAQ:VSTM) Stock Price Passes Above 200-Day Moving Average of $9.47April 10, 2024 | investing.comVerastem CFO sells shares to cover tax obligationsApril 4, 2024 | businesswire.comVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2024 | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Receives Average Rating of "Buy" from AnalystsShares of Verastem, Inc. (NASDAQ:VSTM - Get Free Report) have been assigned an average recommendation of "Buy" from the seven research firms that are presently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 month pricMarch 27, 2024 | markets.businessinsider.comVerastem’s Strategic Advancements and Financial Stability Underscore Buy RatingMarch 22, 2024 | investing.comVerastem director sells over $8,500 in company stockMarch 20, 2024 | finance.yahoo.comVSTM Apr 2024 11.000 callMarch 19, 2024 | markets.businessinsider.comVerastem: Financial Resilience and Promising Drug Pipeline Despite Short-Term LossesMarch 18, 2024 | marketbeat.comRoyal Bank of Canada Reiterates Outperform Rating for Verastem (NASDAQ:VSTM)Royal Bank of Canada reaffirmed an "outperform" rating and set a $32.00 target price on shares of Verastem in a report on Friday.March 18, 2024 | businesswire.comGlobal Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian CancerMarch 16, 2024 | finance.yahoo.comVSTM Apr 2024 14.000 callMarch 14, 2024 | benzinga.comRecap: Verastem Q4 EarningsMarch 14, 2024 | investorplace.comVSTM Stock Earnings: Verastem Misses EPS for Q4 2023 Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Don’t buy a single NVIDIA share before you see this... (Ad)If you feel like NVIDIA is still a good buy - be careful. Billionaires like Steve Cohen, Stanley Druckenmiller and George Soros are ALL dumping NVIDIA... And piling into an overlooked sector... I've prepared a short briefing with all the proof VSTM Media Mentions By Week VSTM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VSTM News Sentiment▼0.030.79▲Average Medical News Sentiment VSTM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VSTM Articles This Week▼122▲VSTM Articles Average Week Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Lexicon Pharmaceuticals News Vanda Pharmaceuticals News XOMA News Agenus News Emergent BioSolutions News Codexis News Achieve Life Sciences News Rigel Pharmaceuticals News Regulus Therapeutics News Sangamo Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VSTM) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
